Silymarin improved IVF outcome in women with polycystic ovary syndrome Download PDF

Background: The most feature of polycystic ovary syndrome (PCOS) is oligomenorrhea, enlarged cystic ovaries and it is the most common cause of chronic anovulation. Because of high level of oxidative stress and inflammation in this patient, we usually have poor IVF outcome. In this study we investigate the effect of Silymarin, the known anti-oxidant agent, on IVF outcome in patient with PCOS. Methods: In this clinical trial, 40 PCOS patients whom underwent IVF were enrolled. All patient received metformin 1500mg/day and case group received additionally Livergol (Silymarin) 210mg/day. Oxidative stress and inflammation parameters were measured in the base and after intervention. Also, the Oocytes retrieved, transferred embryos and pregnancy rate were observed. Results: Our results have shown that Silymarin can reduce oxidative stress and inflammation in PCOS patients. Also, it can improve IVF outcome in this patients.in addition we have shown that this improving effect was independent to body weight. Conclusion: Since, Silymarin is pharmacologically safe and well tolerable, we suggest to improve IVF outcome in PCOS patients, we can use Silymarin as a good adjuvant therapy.